FDA approval

    By Linda Doell

    | 8:00PM 3/11/2011
    Vitalabs Inc. recalled certain lots of its Whey-26 Protein Powder sold under 22 brands because it may be contaminated with salmonella, said the U.S. Food and Drug Administration. So far, no one has gotten sick from eating the powder usually used in protein shakes and smoothies as a diet...

    By The Associated Press

    | 7:15PM 3/09/2011
    0
    The Food and Drug Administration on Wednesday approved the first new drug to treat lupus in 56 years. It's not terribly effective: It only worked for 35% of the patients tested. But experts say the approval could prompt the development of more effective drugs.

    By Melly Alazraki

    | 10:00AM 2/17/2011
    The odds of shepherding a new drug to market in recent years has fallen to nearly one in 10 -- about half of the previous rate, according to a new study released this week. First, a new treatment must survive several layers of clinical studies -- and then the FDA approval process. That trip is getting tougher.

    By Gene Marcial

    | 8:00AM 2/14/2011
    From October 2010 to February 2011, biotech Clinical Data's stock doubled, mostly thanks to FDA approval of its novel antidepressant. But also pushing the stock up -- and making it likely to perhaps double again -- is speculation that a Big Pharma will buy Clinical Data.

    By Melly Alazraki

    | 11:17AM 2/01/2011
    In a surprise move Tuesday, the FDA rejected Orexigen's proposed new diet drug Contrave, saying the company needed to run another study of its cardiovascular risks. With this rejection, all three of a slate of similar diet drugs from competing pharmaceuticals have been turned back by the agency.

    By Melly Alazraki

    | 8:08AM 12/17/2010
    The FDA disappointed AstraZeneca and its investors by not approving its heart drug Brilinta, a blood-thinner that the company -- facing a severe patent cliff -- has high hopes for. If approved, it could be a multibillion-dollar blockbuster. But the FDA wants to see more analyses of results from a major study.

    By Melly Alazraki

    | 9:35AM 12/15/2010
    More than a year after AstraZeneca filed for approval, the FDA will make its decision on Thursday. A large study showed the blood thinner worked better than Plavix for treating acute coronary syndrome -- but approval isn't a sure thing, due in part to some oddities in the study's results.

    By Gene Marcial

    | 7:30AM 12/06/2010
    What's Spectrum's particular allure? Beyond being the subject of takeover rumor, it has two oncology drugs approved by the Food and Drug Administration that are already on the market, plus two other promising drugs that are in late-stage clinical trials.

    By Melly Alazraki

    | 8:45PM 12/01/2010
    Allergan's Lap-Band, a device implanted in the stomach to limit the amount of food that can be ingested, is already on the market to help the very obese lose weight. But now the company hopes to win approval for less obese patients to use the band.

    By Melly Alazraki

    | 1:24PM 11/19/2010
    The FDA has approved Amgen's osteoporosis drug denosumab for use by cancer patients with solid tumors whose disease has metastasized to their bones. The indication to prevent complications such as fractures and bone pain among those patients could boost the drug's sales by billions.